Original Research
John Barron, PharmD, Yiqiong Xie, PhD, Sze-jung Wu, PhD, Jeff White, PharmD, Joseph R. Singer, MD, Bernard Tulsi, MSc, Alan Rosenberg, MD
Evaluating the True Value of High-Cost Therapies for Hepatitis C Infection
Daniel B. Ng, PharmD, MBA, Melissa McCart, PharmD, MS, Christopher Klein, BS, Chelsey Campbell, PharmD, MBA, Robert Schoenhaus, PharmD, Todd Berner, MD
Implications of Big Data Analysis in the Real-World Setting: The Case of Overactive Bladder Treatment
Jordan D. Haag, PharmD, RPh, Amanda Z. Davis, PharmD, RPh, Robert W. Hoel, PharmD, RPh, Jeffrey J. Armon, PharmD, RPh, Laura J. Odell, PharmD, RPh, Ross A. Dierkhising, MS, Paul Y. Takahashi, MD
A Systematic Approach to Medication Therapy Management in Elderly Patients with Chronic Diseases Can Improve Outcomes
Abdullah K. Alahmari, BPharm, PhD candidate, Ziyad S. Almalki, BPharm, PhD candidate, Ahmed K. Alahmari,, Medical Student, Jeff J. Guo, BPharm, PhD
Better Patient Education Needed Regarding Thromboembolic Events Risk in Patients with Cancer
Dramatic Increase in Misuse of Controlled Substances a Concern for All Stakeholders
Continuing Challenges in COPD Management, Despite Its Prevalence and High Economic Burden
Brent M. Tambourine, PharmD, BCPS, Arash Sadeghi, PharmD, Jianing Yang, MD, MS, Karen M. Stockl, PharmD, Heidi C. Lew, PharmD, Brian K. Solow, MD, FAAFP, Josephine N. Tran, PharmD, MS
Anthony M. Louder, PhD, RPh, Amitabh Singh, PhD, Kim Saverno, PhD, Joseph C. Cappelleri, PhD, Aaron J. Aten, PharmD, BCPS, Andrew S. Koenig, DO, FACR, Margaret K. Pasquale, PhD
Challenges in the Assessment of Patient Preferences among RA Therapies
An Ounce of Prevention Is Not a Choice a Patient Gets to Make for Late-Stage Cancer
Page 12 of 21
Results 111 - 120 of 209
Results 111 - 120 of 209